Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

This Parkinson disease (PD) trial will test whether 26 months of citalopram, compared to placebo, can alter the build-up of toxic amyloid-beta plaques in the visuospatial cortex of the brain

cognitive impairment
dopamine
  • 0 views
  • 19 Apr, 2022
  • 1 location
Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression

To provide evidence on the antidepressant efficacy of two therapeutic treatments: pharmacological treatment (citalopram) and psychotherapy treatment, in women diagnosed with breast cancer and

mammogram
  • 0 views
  • 06 Oct, 2021
  • 1 location
Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder

The purpose of this study is to determine if Liposom Forte will enhance the response to antidepressant therapy with citalopram in elderly patients suffering from Major Depressive Disorder (MDD

  • 0 views
  • 02 Aug, 2021
  • 16 locations
Brain Response to Serotonergic Medications in ASD

This study investigates brain response to single acute dose of citalopram, tianeptine, and placebo in males with and without autism spectrum disorder.

pervasive developmental disorder
major depressive disorder
psychiatric disorder
Accepts healthy volunteers
autism
  • 96 views
  • 06 May, 2022
  • 1 location
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD) (DOTS-AD)

Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.

major depressive disorder
selective serotonin reuptake inhibitors
duloxetine
depressive disorder
citalopram
  • 420 views
  • 26 Mar, 2022
  • 1 location
Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder

One-third of the patients with major depressive disorder do not respond to conventional antidepressants that act through the mono-aminergic system. The available treatment modalities, including SSRIs, are slow to act and have a lag time before showing improvement in symptoms of patients. To overcome these treatment hurdles, add-on therapy to …

  • 0 views
  • 06 Nov, 2021
  • 1 location
First choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic (FIAT)

serotonin reuptake inhibitors (SSRI), e.g. citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, in depression with anxiety and insomnia is preferable trazodone and in severer disorders

  • 0 views
  • 10 Apr, 2022